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Cyclooxygenase-2(COX-2) overexpression promotes inflammation and tumorigenesis. COX-2 expression in response to di-
verse stimuli is tightly controlled to avoid persistent overexpression. 5-methoxyindole metabolites of L-tryptophan
represent a new class of compounds that control COX-2 expression at the transcriptional level. Two of the metabolites, the
newly discovered 5-methoxytryptophan (5-MTP, also known as cytoguardin) and N-acetyl 5-methoxytryptamine (melatonin)
are the focus of this review. 5-MTP is produced by mesenchymal cells such as fibroblasts via 5-hydroxytryptophan (5-HTP).
It inhibits COX-2 transcriptional activation induced by diverse proinflammatory and mitogenic factors. Cancer cells are
deficient in cytoguardin production which contributes to COX-2 overexpression. Fibroblast-generated 5-MTP is capable
of restoring the control of COX-2 overexpression in cancer cells. 5-MTP blocks cancer cell migration and invasion
in vitro and inhibits tumor growth and cancer metastasis in a xenograft model. Melatonin possesses similar COX-2
suppressing and anti-cancer properties albeit at supra-pharmacological concentrations. By contrast, 5-hydroxyindole
metabolites of L-tryptophan such as 5-hydroxytryptamine (serotonin), 5-hydroxytryptophol and other serotonin catabolites
do not control COX-2 expression. 5-hydroxytryptophan inhibits COX-2 expression through conversion to 5-MTP. The
physiological relevance of 5-MTP as an endogenous regulator of inflammation and cancer metastasis remains to be
investigated. On the other hand, 5-methoxyindole metabolites of tryptophan are valuable lead compounds for
development of new anti-inflammatory drugs and cancer chemoprevention.
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Introduction
Cyclooxygenase-2 (COX-2, also known as Prostaglandin
endoperoxide synthase-2 or PGH synthase-2; gene name
is PTGS-2) is expressed in diverse cells notably inflam-
matory cells. At resting cellular state, expression of
COX-2 is restricted to a very low level often barely de-
tectable on the Western blotting. Upon cellular stimula-
tion with cytokines, lipopolysaccharides (LPS), growth
and mitogenic factors, there is a burst of expression of
COX-2 resulting in robust production of prostaglandin
G2 (PGG2) and PGH2 (PGG2 and PGH2 are collectively* Correspondence: kkwugo@gmail.com
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unless otherwise stated.called PG endoperoxides) [1,2]. PGH2 is an intermediary
metabolite in prostaglandin biosynthesis. It is converted
to PGE2, PGF2α, PGD2, thromboxane A2 (TXA2) and
prostacyclin (PGI2) by specific terminal enzymes i.e.
PGE synthase, PGF synthase, PGD synthase, thromb-
oxane synthase and PGI synthase, respectively. Produc-
tion of PGs, TXA2 and/or PGI2 is governed by the level
of the induced COX-2 and the expression of the down-
stream terminal enzymes. Prostaglandin production is
cell-specific. For example, a majority of prostanoids pro-
duced by macrophages are PGE2 and TXA2, while the
major prostanoid produced by vascular endothelial
cells is PGI2. Selective prostanoid production in a cell-
dependent manner permits the cells to carry out their
unique physiological functions and participate in patho-
logical processes. Since COX-2 occupies a key position
in cell-selective prostanoid productions, it plays multiple. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reproduction, and mediates a number of important patho-
logical conditions, notably inflammation and tumorigen-
esis. Persistent overexpression of COX-2 is of particular
importance in mediating inflammatory tissue damages
and cancer growth and metastasis. Persistent COX-2
overexpression is due to continuous and/or repeated
stimulation of COX-2 expression in inflammatory cells by
showers of proinflammatory cytokines or endotoxins. It
could also be due to deregulation of COX-2 expression in
cancer cells.
Persistent stimulation of COX-2 expression in
inflammatory cells
Macrophages are at the front line of tissue inflammation.
In response to stimulation by immune mediators, endo-
toxins and cytokines, they express abundant COX-2 and
generate PGE2 and TXA2 [3]. Tissue fibroblasts are also
important inflammatory cells. At resting state, fibro-
blasts function as a supporter of tissue integrity. They
lay down connective tissues and provide cellular support
for tissues. However, upon tissues injuries, they migrate
to the injured sites where they change to a proinflamma-
tory phenotype [4]. In response to exogenous stimuli,
they express robust COX-2 and generate abundant
PGE2 to mediate tissue inflammation [5,6].
Proinflammatory mediators stimulate COX-2 tran-
scription in diverse cell types such as macrophages,
fibroblasts and endothelial cells by a common mechan-
ism. Upon stimulation by LPS, IL-1β, TNFα or PMA,
human fibroblasts exhibit enhanced binding of NF-κB
(p65/p50), C/EBPβ, AP-1 and CREB-2/ATF2 concur-
rently to their respective cognitive sites on COX-2
promoter/enhancer region within 500-bp from the tran-
scription start sites [7-9]. Furthermore, p300 binding to
the enhancer sites is correspondingly increased [10,11].
Proinflammatory mediators stimulate P300 histone ace-
tyltransferase (HAT) activity which in turn augments
transactivators binding by acetylation of chromatin his-
tone and the transactivators (p65, C-Jun, C/EBPβ and
CREB-2)[12]. Prolonged continuous and/or repeated
stimulation by exogenous insults has been shown to re-
sult in persistent overexpression of COX-2 and excessive
production of proinflammatory prostaglandins in fibro-
blasts, macrophages or endothelial cells. COX-2 overex-
pression is considered to play a major role in human
inflammatory disorders such as rheumatoid arthritis and
degenerative joint diseases as evidenced by effective con-
trol of joint inflammation by selective COX-2 inhibitors
[13,14].
Deregulation of COX-2 expression in cancer cells
There is ample evidence that COX-2 is constitutively
overexpressed in cancer cells [15]. Malignant tumors areskillful in recruiting inflammatory, immune and vascular
cells to create an inflammatory microenvironment, where
proinflammatory cytokines released by macrophages,
fibroblasts and endothelial cells stimulate cancer COX-2
expression. Furthermore, cancer cells produce growth fac-
tors to stimulate COX-2 expression in the inflammatory
and stromal cells within the tumor microenvironment
[16]. The positive regulatory loop leads to persistent
COX-2 overexpression not only in cancer cells but also in
the microenvironmental stromal and inflammatory cells.
This results in robust production of PGE2 and other pros-
tanoids which promote cancer growth and metastasis.
It was demonstrated that COX-2 overexpression alters
cell phenotypes, which are characterized by reduced re-
sponse to apoptotic signals, increased cellular migratory
activity and through production of matrix metallopro-
teinases (MMPs), increased cell invasiveness [17,18].
Thus, COX-2 overexpression in cancer cells and cancer
microenvironment represents a major force for tumor
growth and cancer metastasis. The causal role of COX-2
overexpression in tumorigenesis is supported by strong
clinical and experimental evidence. Selective small-
molecule inhibitors of COX-2 catalytic activity (coxibs),
prevent growth of carcinogen-induced cancer in experi-
mental animals or cancer induced by genetic modifica-
tion [19-21].
The exact mechanism by which COX-2 is constitu-
tively overexpressed in cancer cells is not entirely clear.
There are suggestions that aberrant Wnt/β-catenin sig-
naling due to mutation of APC (adenomatous polyposis
coli), β-catenin, or glycogen synthase Kinase 3 (GSK3)
may be a common mechanism by which COX-2 expres-
sion is enhanced in gastrointestinal cancers, notably
colorectal cancer [22-25]. Under physiological conditions
in normal cells, β-catenin is sequestered and degraded in
a destruction complex composed of APC, GSK-3, axin
and casein kinase 2(CK2). Loss of function and mutation
of APC in colorectal cancer or GSK-3 in gastric cancer
disrupts the function of the destruction complex and lib-
erates β-catenin. β-catenin enters nucleus where it forms
a complex with Tcf(T cell factor), binds to the promoter
region and activates the transcription of a number of
genes important in cell growth, and tumorigenesis. It
was reported that β-catenin/Tcf binds to the promoter
region of COX-2 and enhances COX-2 expression [26].
Other signaling and transcriptional pathways are likely
to be dysregulated in different cancers. Further investiga-
tions are necessary to discern the dysregulated mechan-
ism for each type of cancer.
COX-2 in cancer cells and the microenvironmental
stromal cells catalyze the formation of several prosta-
noids among which PGE2 is considered to be the most
important in promoting cancer cell growth and metasta-
sis [27]. PGE2 is pleiotropic and promotes cancer cell
Figure 1 Melatonin synthesis. Abbreviations are: TPH-2, Tryptophan
hydroxylase-2; AA – DC, aromatic aminoacid decarboxylase; AA-NAT,
arylalkylamine N-acetyltransferase; HIOMT, hydroxyindole O-methyltransferase.
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[28,29]. A key signaling pathway via which PGE2 induces
cancer growth is Wnt/β-catenin pathway [30,31]. PGE2
binds to EP2 receptor and induces dissociation of Gs
into βγ and α subunits. Gs βγ subunit activates PI-3
K/Akt. Akt inhibits GSK-3β resulting in release of
β-catenin from the APC-GSK-3β-axincomplex. Under
hypoxic conditions, β-catenin complexes with hypoxia
inducing factor 1 (HIF-1) which drives the expression of
vascular endothelial growth factor (VEGF) to enhance
angiogenesis. The α subunit interacts with axin of the
APC-GSK-3β-axin complex which triggers release of
β-catenin, further enhancing the expression of prolifera-
tive and angiogenic genes. Gsβγ subunit also activates
Ras/Raf/Mek/Erk pathway resulting in enhanced expres-
sion of Bcl-2, conferring resistance to apoptosis.
PGE2 stimulates cancer cell migration and invasion by
inducing cancer cell cytoskeletal reorganization, produc-
tion of MMPs and epithelial-mesenchymal transition
(EMT) [32-35]. The actions of PGE2 on cell prolifera-
tion, resistance to apoptosis, migration and invasion
contribute to the effect of COX-2 overexpression on
cancer cells. It may be concluded that through PGE2
productions, COX-2 overexpression plays a critical role
in promoting cancer growth and metastasis.
Control of COX-2 expression by 5-methoxytryptophan
For a long time it has been a curious question whether
COX-2 expression under inflammatory challenge is pro-
tected by endogenous factors. Hence, we were intrigued
when we serendipitously identified COX-2 suppressing
activity in the conditioned medium (CM) of cultured hu-
man foreskin fibroblasts, Hs68 [36]. Chemical analysis of
semi-purified fractions of CM revealed that the COX-2
suppressing activities reside in the small molecule frac-
tion (Mr < 500 daltons). NMR analysis suggested pres-
ence of indoles in the active molecular fraction. The
COX-2 suppressing activity in the CM fraction was
named cytoguardin [36].
The chemical nature of cytoguardin was recently iden-
tified by comparative metabolomics. Based on the obser-
vations that cancer cells do not release detectable
cytoguardin activity in the conditioned medium, meta-
bolomic profiles of purified fraction of fibroblasts CM vs
that of A549 lung cancer cell CM were obtained by
ultrahigh performance liquid chromatography (UPLC)
coupled to quadruple time of flight (Q Tof) mass
spectrometry(MS). Analysis of the spectra of chromatog-
raphy and mass spectrometry reveals striking differences.
The fibroblast CM contains several m/z peaks which are
barely detectable in A549 CM [37]. Two major peaks,
m/z 276.1 and m/z 262.1 were selected for more detailed
analysis. Through chemical database search and bio-
chemical deductions, m/z 262.1 was determined to be aknown compound, i.e. 5-hydroxytryptophan (5-HTP).
5-HTP is a key intermediate metabolite of serotonin
biosynthesis and melatonin biosynthesis. In neuronal
cells, L-tryptophan is converted to 5-HTP by tryptophan
hydroxylase-2 (TPH-2) and 5-HTP is converted to
5-hydroxytryptamine (serotonin, 5-HT), by aromatic amino
acid decarboxylase [38]. In pineal cells, 5-hydroxtryp-
tamine is further converted to N-acetyl-5-HT by arylal
kylamine N-acetyltransferase (AA-NAT) and N-acetyl-
5-HT is converted to melatonin (N-acetyl-5-methoxytry-
ptamine) by hydroxyindole-O-methyltransferase (HIOMT)
[39] (Figure 1). Interestingly, addition of 5-HTP to fibro-
blasts enhanced COX-2 suppressing activity and increased
the m/z 276.1 peak suggesting that 5-HTP is converted to
m/z 276.1. On the chemical database, one of the candidate
molecules for m/z 276.1 is 5-methoxytryptophan (5-MTP).
As little is known about 5-MTP production by mammalian
cells, 5-MTP production by fibroblasts must be validated.
Analysis of fibroblast CM by 5-MTP specific enzyme im-
munoassay confirmed the presence of abundant 5-MTP. By
contrast, 5-MTP in A549 CM was barely detectable and
not significantly different from that in serum-containing
culture medium. Importantly, addition of 5-HTP to Hs68
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On the other hand, 5-HTP did not boost 5-MTP in cancer
cells.
Since 5-MTP is structurally similar to melatonin, it
was reasoned that 5-MTP could be converted from
5-HTP by HIOMT. This notion was supported by the
expression of HIOMT proteins in Hs68 cells. Import-
antly, silencing of HIOMT with selective siRNA resulted
in aborted 5-MTP in the CM and abrogation of COX-2
suppression [37]. Hs68 fibroblasts express TPH-1 iso-
form and silencing of TPH-1 with siRNA also abolished
5-MTP production and COX-2 suppression. Addition ofFigure 2 Cytoguardin (5-MTP) biosynthesis in human fibroblasts.5-HTP rescued 5-MTP production and COX-2 suppres-
sion. Taken together, these results demonstrate that
fibroblasts possess functional TPH-1 and HIOMT en-
zymes to synthesize 5-MTP which is released to extra-
cellular milieu to act as an autacoid to control COX-2
expression. A tentative 5-MTP synthetic pathway is
illustrated in Figure 2.
Cytoguardin restores cancer cell COX-2 suppressing
activity
Constitutive COX-2 overexpression in cancer-cells is
attributed to uncontrolled transcriptional activation by
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release cytoguardin, defective 5-MTP production may
contribute to COX-2 overexpression. In this case, CM
from fibroblasts should be able to suppress cancer COX-
2 expression. This was proved by co-cultures of Hs68
with A549 cells in a Boyden Chamber. Hs68 at sufficient
cell numbers were effective in suppressing A549 COX-2
expression. Direct incubation of A549 cells with Hs68
fibroblast CM exerted comparable dose-dependent effect.
5-MTP exerted a concentration-dependent inhibition of
A549 COX-2 expression. 5-MTP at 10 μM significantly
suppresses COX-2 expression and maximally inhibits
COX-2 expression at 50–100 μM [37].
5-MTP inhibits cancer cell migration/invasion and cancer
growth and metastasis
Since COX-2 overexpression promotes cancer cell prolif-
eration and migration, it was stipulated that 5-MTP,
through its suppression of COX-2 expression is capable
of blocking cancer growth and metastasis. Indeed,
addition of 5-MTP to the cultured medium of A549 cells
resulted in reduction of A549 migration as analyzed in a
transwell assay [37]. Furthermore, 5-MTP inhibited
A549 invasion through matrigel in the transwell assay
[37]. Concentrations of 5-MTP required for inhibition of
migration were corresponding to those needed to inhibit
invasion which were correlated with COX-2 suppression
[37]. Thus, it is likely that 5-MTP inhibits cancer cell
migration and invasion through blocking COX-2 tran-
scriptional activation.
5-MTP possesses anti-cancer effects in vivo. Intraperi-
toneal injection of 5-MTP into a murine A549 xenograft
tumor model resulted in a time-dependent reduction of
cancer growth. Tumor volume at 7 weeks after 5-MTP
administration was ~50% of that of vehicle control.
5-MTP also significantly reduced metastatic lung nod-
ules [37]. These results support the notion that 5-MTP
suppresses cancer growth and metastasis through inhib-
ition of COX-2 overexpression.
Control of COX-2 expression by other 5-HTP metabolites
A large number of 5-HTP metabolites have been identi-
fied, among which serotonin and melatonin are of
physiological important. Serotonin is catabolized to form
5-hydroxyindole compounds notably 5-hydroxyindole
acetic acid, and 5-hydroxytryptophol. It is interesting to
note that except for 5-HTP, none of the 5-hydroxyindole
catabolites of serotonin is active in suppressing COX-2
expression [37]. Serotonin also does not possess COX-2
suppressing action at concentrations up to 1 mM [40].
By contrtast, 5-methoxyindole metabolite such as mela-
tonin inhibits COX-2 expression at millimolar concen-
trations. These results suggest that the 5-methoxyindole
moiety is important in controlling COX-2 expression.Melatonin suppresses COX-2 expression
Melatonin is produced primarily in pineal gland by pine-
alocytes, and is involved in regulating sleep and other
biological activities associated with circadian rhythm
[41]. Interestingly, several studies have reported that
melatonin possesses COX-2 suppressing actions. Mela-
tonin at supra-pharmacological concentrations (≧1 mM)
was reported to inhibit proinflammatory mediator-
induced COX-2 expression at the transcriptional level
[40,42]. Melatonin was also reported to control COX-2
expression in colitis in a rat model [43]. As the blood
melatonin concentrations are generally less than 1nM,
the physiological role that melatonin plays in controlling
COX-2 and COX-2 mediated pathophysiological pro-
cesses is questionable. However, recent studies report
that macrophages produce melatonin in response to
stimulation by LPS, cytokines and PMA [44] and it
was suggested that tissue injuries such as ischemia-
reperfusion injury stimulates inflammatory cells to gen-
erate abundant melatonin [45]. As the local melatonin
concentration has not been determined, it remains to be
investigated whether melatonin may be a functionally
important local hormone to defend against excessive in-
flammation and tissue damage.
Melatonin is catabolically converted to indole com-
pounds via three major pathways: (1) degradation by
cytochrome p450s i.e. CYP1A2, CYP1A1 and CYP1B1
to 6-hydroxy-melatonin which is further converted to
6-sulfatoxy-melatonin by a sulfotransferase; (2) conver-
sion to N1 acetyl-N2 formyl 5- methoxykynuramine
(AFMK) by myeloperoxidase or indoleamine 2, 3 dioxy-
genase (IDO) which is further converted to N1 acetyl-
5-methoxykynuramine (AMK) by formamidases; (3)
Deacetylation to form 5-methoxytryptamine (5-MT) [46]
(Figure 3). Two of the 5-methoxyindole metabolites,
i.e. AFMK and AMK were reported to inhibit COX-2 ex-
pression in macrophages [42].
The inhibitory effects of melatonin on cancer cell
proliferation have been extensively investigated. Mela-
tonin reduces proliferation of several types of cancer
cells, notably MCF7 breast cancer cells. Early reports
indicate that melatonin at the physiological concen-
tration (<1 nM) inhibited MCF-1 cell proliferation
[47]. However, subsequent studies failed to confirm
suppression of MCF-1 proliferation by melatonin at
the low concentrations. Others have reported the
inhibition of MCF-7 proliferation by melatonin at
millimolar concentrations [48]. The reasons for the
discrepancy are unclear but could be attributed to
variations in experimental conditions and variations
of MCF-7 cells [49]. Melatonin at ≧1 mM inhibits
MDA-MB-361 cancer cell proliferation and induces
apoptosis which is correlated with suppression of
COX-2 expression and PGE2 production [50].
Figure 3 Major pathways of melatonin catabolism. CYP denotes cytochrome p450 1A2, 1A1, 1B1; MPO, myeloperoxidase; IDO, indoleamine
2, 3-dioxygenase.
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been evaluated in animal models and the results are in-
consistent [51]. Variations in the in vivo data, like those
in the in vitro cell studies are influenced by melatonin
dosing. Furthermore, melatonin in circulation is rapidly
degraded into several catabolites some of which may
possess oncostatic activity. Length of treatment may be
another confounding factor influencing the effect of
melatonin.
Therapeutic potentials of 5-methoxyindole metabolites
5-methoxyindole compounds, notably cytoguardin (5-MTP)
and melatonin have potentials as a therapeutic agent for
inflammatory disorders and as a cancer chemopreventive
agent. As these compounds are endogenously produced,
they have the advantage of having predictable adverse ef-
fects as long as they are not too excessive. They are differ-
ent from the selective COX-2 inhibitors in that they only
block COX-2 overexpression induced by proinflammatory
mediators and mitogenic factors. As they do not inhibit
the basal vascular endothelial cell COX-2, as COX-2 in-
hibitors do, they will avoid the cardiovascular complica-
tions of selective COX-2 inhibitors [52].
A number of clinical trials have been carried out to
evaluate the efficacy of melatonin in treating cancer. The
results are inconsistent, which may be attributed to
small patient numbers and variable dosing. Interestingly,meta-analysis of 21 clinical trials revealed a beneficial ef-
fect of melatonin on one-year survival and tumor re-
sponse. Furthermore, it reduces the serious adverse
effects of concomitant chemotherapy [53]. Large ran-
domized control trials are needed to validate the efficacy
of melatonin in treating human cancers.
An attractive idea is emerging regarding the use of
melatonin as an adjuvant to enhance the efficacy of con-
ventional cancer chemotherapy or biotherapy [53]. This
idea has not been supported by solid clinical trials re-
sults and will require further investigation.
Cytoguardin is a promising lead compound for therapy
of a broad spectrum of inflammation-related diseases in-
cluding cancer chemoprevention. A major advantage is
that the effective concentrations of 5-MTP for control
of cancer growth and metastasis in vitro and in vivo are
in line with the normal human serum concentrations
(unpublished data).
Conclusion
L-tryptophan, in addition to being an essential amino acid
for protein synthesis, serves as an important precursor
molecule for production of active metabolites involved in
regulation of immunity, inflammation, neurotransmission
and circadian rhythm. Those biologically active metabo-
lites are produced via two major pathways: (1) indolea-
mine 2, 3 dioxygenase (IDO) pathway which generates
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way which was originally thought to produce neurotrans-
mitters and neural function modulators notably serotonin
and melatonin. Discovery of 5-MTP pathway adds a new
dimension to the functional diversity of tryptophan and
complexity of tryptophan metabolism.
The TPH pathway generates a series of 5-methox-
yindole metabolites whose synthetic and catabolic path-
ways are not fully understood. Take 5-MTP as an
example, the synthetic pathway may not have been com-
pletely uncovered. There may be intermediary steps to
be further discovered. It is of interests to note that
5-MTP synthesis shares with melatonin synthesis com-
mon enzymatic steps, i.e. TPH and HIOMT. However, a
striking difference between 5-MTP and melatonin
biosynthesis is the decarboxylation step which is re-
quired for melatonin but not for 5-MTP production.
Metabolomics analysis of fibroblast CM detects only
5-methoxyindole derivatives of 5-MTP but not mela-
tonin or its catabolites. The results imply that 5-MTP
vs. melatonin production is cell type-specific. Pineal,
retinal and enteroendocrine cells are equipped with
enzymes to produce melatonin while peripheral non-
neural cells such as fibroblasts and vascular cells are
endowed with enzymes to catalyze the formation of
cytoguardin. Melatonin and its metabolites are primarily
involved in regulating brain functions whereas cytoguar-
din and its metabolites control inflammatory responses
and tumorigenesis.
Melatonin was reported to inhibit p300 HATand NF-κB
activation induced by proinflammatory mediators [40,50].
Unpublished data reveal that 5-MTP inhibits p300
HAT activation at concentrations comparable to its inhib-
ition of COX-2 expression. These results suggest that
5-methoxyindole metabolites target at least in part p300
HAT activation and NF-κB and consequently blocks the
transactivation of not only COX-2 but also inducible nitric
oxide synthase [40,43] and proinflammatory cytokines.
5-methoxyindole metabolites of L-tryptophan encom-
pass a novel class of endogenously produced compounds
to modulate the inflammatory response to environmen-
tal insults and control neoplastic growth and cancer
metastasis. A critical issue regarding the physiological
role of 5-methoxyindole metabolites, notably 5-MTP is
whether under pathophysiological conditions, 5-MTP is
produced in sufficient concentrations to combat exces-
sive inflammatory reactions and tumorigenesis. Relevant
to this issue is whether 5-MTP acts as a circulating hor-
mone or as a local autacoid. Additional work is needed
to resolve this issue. On the other hand, there seems
little doubt that 5-MTP has a great potential to be con-
sidered as a candidate drug or as a lead compound
for synthesizing new agents to treat or prevent diverse
human inflammatory disorders and cancers.Competing interests
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